| Literature DB >> 23840922 |
Khushwant S Bhullar1, H P Vasantha Rupasinghe.
Abstract
Aging leads to numerous transitions in brain physiology including synaptic dysfunction and disturbances in cognition and memory. With a few clinically relevant drugs, a substantial portion of aging population at risk for age-related neurodegenerative disorders require nutritional intervention. Dietary intake of polyphenols is known to attenuate oxidative stress and reduce the risk for related neurodegenerative diseases such as Alzheimer's disease (AD), stroke, multiple sclerosis (MS), Parkinson's disease (PD), and Huntington's disease (HD). Polyphenols exhibit strong potential to address the etiology of neurological disorders as they attenuate their complex physiology by modulating several therapeutic targets at once. Firstly, we review the advances in the therapeutic role of polyphenols in cell and animal models of AD, PD, MS, and HD and activation of drug targets for controlling pathological manifestations. Secondly, we present principle pathways in which polyphenol intake translates into therapeutic outcomes. In particular, signaling pathways like PPAR, Nrf2, STAT, HIF, and MAPK along with modulation of immune response by polyphenols are discussed. Although current polyphenol researches have limited impact on clinical practice, they have strong evidence and testable hypothesis to contribute clinical advances and drug discovery towards age-related neurological disorders.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23840922 PMCID: PMC3690243 DOI: 10.1155/2013/891748
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Neuroprotection by polyphenols against neurological disorders.
Neuroprotective signal transduction by polyphenols.
| Pathway | Polyphenol | References |
|---|---|---|
| P13K/AkT pathway | Resveratrol | [ |
| Baicalein | [ | |
| NF | Kaempferol, acacetin, apigenin, luteolin | [ |
| Soybean isoflavones | [ | |
| Fisetin | [ | |
| Resveratrol | [ | |
| Baicalein | [ | |
| Silymarin | [ | |
| Tetrahydroxystilbene | [ | |
| Quercetin | [ | |
| Catechin hydrate | [ | |
| STAT pathway | Silymarin | [ |
| PPAR pathway | Baicalein | [ |
| Resveratrol | [ | |
| Pterostilbene | [ | |
| Nrf2/HO1/ARE pathway | Epicatechin | [ |
| Resveratrol | [ | |
| HIF-1 | Xanthohumol | [ |
| Resveratrol | [ | |
| MAPK | Flavone glycoside | [ |
| Quercetin | [ |
Modulation of cytokines and inflammatory targets by polyphenols.
| Polyphenol | Target | References |
|---|---|---|
| EGCG | IL-1 | [ |
| IL-6 | [ | |
| MCP-1 | [ | |
| CXCL 10, | [ | |
| CCL22, CCL 17 | [ | |
| TGF | [ | |
| Resveratrol | MCP-1 | [ |
| Catechin | MCP-1 ( | [ |
| Caffeic acid | CCR1, CCR2 | [ |
| Quercetin | IL-1 | [ |
| COX-2 | [ | |
| COX-20, TRAF1 | [ | |
| Apple polyphenols | IL-1 | [ |
Modulation of mitochondrial targets by polyphenols.
| Target | Polyphenol | Effect | References |
|---|---|---|---|
| AP-1 | EGCG | Downregulation | [ |
| Bad/Bax | Resveratrol | Downregulation | [ |
| Ferulic acid | Downregulation | [ | |
| Bcl-2 | Lutein | Upregulation | [ |
| Baicalein | Upregulation | [ | |
| Cox-2 | Lutein | Downregulation | [ |
| Hesperidin | Downregulation | [ | |
|
| Downregulation | [ | |
| GCLM | Chrysin, apigenin, luteolin | Upregulation | [ |
| GCLC | Chrysin, apigenin, luteolin | Upregulation | [ |
| GPX | EGCG | Upregulation | [ |
| Red wine polyphenols | Upregulation | [ | |
| 3,3′,5,5′-tetra-t-butyl-biphenyl-4,4′-diol | Upregulation | [ | |
| HO-1 | Butein, apigenin | Upregulation | [ |
| Luteolin | Upregulation | [ | |
| IFN- | Quercetin | Downregulation | [ |
| JNK | Quercetin | Downregulation | [ |
| EGCG | Downregulation | [ | |
|
| Downregulation | [ | |
| JUN | Quercetin | Downregulation | [ |
| SOD | Phloridzin | Upregulation | [ |
Figure 2Chemical structure of polyphenols with therapeutic use in age-related neurological diseases.